Within the cerebral infarction treatment market, Tissue Plasminogen Activators (tPA) held a 41.55% share in 2025, reflecting their established role in acute stroke care where rapid clot dissolution is central to time-sensitive intervention. This leadership is maintained through the fact that tPA remains closely tied to frontline treatment pathways for eligible cerebral infarction cases, especially in hospital settings that prioritize immediate reperfusion to limit neurological damage. Its position is reinforced by clear clinical use in urgent management rather than longer-cycle therapy decisions, which supports consistent demand in the cerebral infarction treatment market.

Anticoagulants are emerging as the fastest-growing drug class in the cerebral infarction treatment market as treatment strategies increasingly extend beyond the initial acute event toward ongoing prevention of recurrent episodes. Their momentum is aided by practical use in patients requiring sustained clot-risk management, making them more relevant in longer-duration care pathways than alternatives focused mainly on emergency intervention. As patient management becomes more continuous and recurrence prevention gains attention, anticoagulants are expanding faster because they align with the need for broader post-event therapeutic coverage in the cerebral infarction treatment market.

Type Segment Analysis: Ischemic Stroke (Largest Segment) vs Hemorrhagic Stroke (Fastest-Growing Segment)

Ischemic Stroke accounted for the largest share of the cerebral infarction treatment market in 2025, aided by its central relevance to treatment demand across diagnosis, emergency response, and follow-on medical management. The segment leads because cerebral infarction treatment is fundamentally associated with restoring or supporting blood flow in blockage-related events, which keeps ischemic stroke at the core of therapeutic utilization. Its share remains highest as treatment pathways, drug use patterns, and hospital intervention models are more directly aligned with this stroke type across routine clinical practice.

Hemorrhagic Stroke is the fastest-growing segment in the cerebral infarction treatment market due to rising attention to specialized treatment needs that differ materially from ischemic care pathways. Growth is being influenced by the practical requirement for more targeted management in complex stroke presentations, where treatment decisions are highly condition-specific and often demand intensive monitoring and intervention. Compared with the more established ischemic segment, hemorrhagic stroke is gaining momentum as care delivery increasingly adapts to differentiated stroke management requirements in the cerebral infarction treatment market.